ClinicalTrials.gg
Not yet recruitingNCT07371754SWINGUpdated Jan 28, 2026

Shear Wave Elastography of Intercostal Muscles for the Non-invasive Assessment of the Work of BreathinG

An observational study in COPD and Healthy Adult, sponsored by Groupe Hospitalier du Havre. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Groupe Hospitalier du Havre · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre — 3 open to participants now, 3 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Groupe Hospitalier du Havre.

Started
2026
with 1 other
Observational
5 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 9th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pulmonary Disease, Chronic Obstructive by Groupe Hospitalier du Havre, or all of them as a file.
02

Study summary

Quantifying respiratory effort is a key step in physiological and clinical research on exercise tolerance, mechanisms of fatigability, and ventilatory impairment. To date, reliable assessment relies on an invasive method: esophageal pressure (Pes) measurement using a balloon catheter inserted into the esophagus. Although Pes provides an indirect estimate of pleural and intrathoracic pressure, it is uncomfortable for patients, requires dedicated equipment, and may limit study participation.

In critically ill patients, a noninvasive approach to quantify respiratory effort would have major clinical and scientific value. In acute respiratory distress, accurately tracking the intensity and evolution of respiratory effort could support earlier therapeutic decision-making.

Shear Wave Elastography (SWE) is an ultrasound technology enabling very high acquisition rates and estimating tissue stiffness from shear-wave propagation induced by an acoustic impulse. Because muscle stiffness is strongly related to force produced during contraction, we hypothesize that intercostal muscle stiffness measured by SWE correlates with respiratory work and increases with rising inspiratory load.

03

Conditions studied

  • COPD
  • Healthy Adult

Keywords

  • Shear wave elastography
  • Intercostal muscles
  • work of breathing
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults (≥18 years) will be enrolled in two cohorts: (1) healthy adult volunteers and (2) adult patients with chronic obstructive pulmonary disease (COPD), stage 3-4. A total of 20 participants will be recruited (10 COPD patients and 10 healthy volunteers). Each participant will complete a single study visit (\~45 minutes) involving standardized breathing/inspiratory loading while intercostal muscle ultrasound shear wave elastography is recorded, with concurrent physiological reference measurements to quantify respiratory effort.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult patient with (COPD), stage 3-4.

Healthy adult volunteer.

Exclusion criteria

Exclusion Criteria:

Refusal to participate or withdrawal of consent.

Age \< 18 years.

> 35 kg/m².

Pregnancy or breastfeeding.

Inability to understand instructions or cooperate (cognitive impairment, language barrier).

Neurological condition affecting breathing (e.g., recent stroke, ALS, myopathy).

Thoracic condition limiting access to the intercostal muscles (e.g., major chest wall deformity, surgical scar).

Recent thoracic or abdominal surgery (\< 3 months).

Known esophageal disease (stricture, achalasia, severe esophagitis, diverticulum, history of perforation).

ENT or tracheal abnormality preventing probe insertion (e.g., tumor, malformation, tracheostomy).

Swallowing disorders or risk of aspiration.

Recent exacerbation (\< 6 weeks).

Oxygen therapy > 2 L/min during exertion.

Hemodynamic instability.

Not affiliated with a social security scheme.

Legally protected persons (as defined by law).

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Healthy adults

    Participant without respiratory, muscle or thoracic abnormalities

    Diagnostic Test: Intercostal muscle shear wave elastography (SWE) during standardized inspiratory loading

  • COPD group

    Patients with COPD

    Diagnostic Test: Intercostal muscle shear wave elastography (SWE) during standardized inspiratory loading

Interventions

  • Diagnostic testIntercostal muscle shear wave elastography (SWE) during standardized inspiratory loading

    Ultrasound shear wave elastography (SWE) is performed to quantify intercostal muscle stiffness at rest and during standardized inspiratory loading/controlled breathing. SWE acquisitions are synchronized with physiological reference recordings (e.g., esophageal pressure and/or diaphragm EMG when available) to estimate and track respiratory effort/work noninvasively.

    Also known as: Ultrasound shear wave elastography of intercostal muscles

06

What researchers measure

Primary outcomes

  1. Correlation between intercostal muscle stiffness (SWE) and respiratory effort (esophageal pressure-time product)

    Intercostal muscle stiffness (kPa) measured by shear wave elastography is correlated with respiratory effort quantified by the esophageal pressure-time product (PTPes; cmH2O·s/min) across the standardized inspiratory loading protocol (within each cohort).

    Time frame: During a single study visit (≈45 minutes), at rest and at each standardized inspiratory load level

Secondary outcomes

  1. Within-subject change in intercostal muscle stiffness (SWE) across inspiratory load levels

    Intercostal muscle stiffness (kPa) measured by shear wave elastography (SWE) will be assessed within participants across the different inspiratory load levels.

    Time frame: Single study visit: during the inspiratory loading protocol (no resistance, then 25%, 50%, and 75% of maximal inspiratory pressure [PiMax])

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data (IPD) will be made available upon reasonable request. Requests will be reviewed on a case-by-case basis and, if approved, de-identified data and relevant documentation (e.g., protocol and data dictionary) will be shared under an appropriate data use agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2027, 12 months later.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 12 months is below that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Jan 28, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07371754
Lead sponsor
Groupe Hospitalier du Havre
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Jan 28, 2026

Study contacts

Clément Medrinal
Contact
medrinal.clement.mk@gmail.com
+33664615110
Angélique Picard
Contact
Angelique.picard@ch-havre.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion